Ambudkar SV et al.
Biochemical, cellular, and pharmacological aspects of the multidrug transporter.
Ann Rev Pharmacol Toxicol 1999;39:361-398.
Appelbaum FR et al.
Age and acute myeloid leukemia.
Blood 2006;107:3481-3485.
Berman E et al.
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
Blood 1991;77:1666-1674.
Bishop JF et al.
A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
Blood 1996;87:1710-1717.
Booser DJ, Hortobagyi GN:
Anthracycline antibiotics in cancer therapy. Focus on drug resistance.
Drugs 1994;47:223-258.
Bradstock KF et al.
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.
Blood 2005;105:481-488.
Büchner T et al.
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Blood 1999;93:4116-4124.
Büchner T et al.
Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies.
Leuk Res 2002;26:1073-1075.
Cheson BD et al.
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
J Clin Oncol 2003;21:4642-4649.
Ehninger G et al.
Pharmacokinetics and metabolism of mitoxantrone. A review.
Clin Pharmacokinet 1990;18:365-380.
Elgemeie GH.
Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites.
Curr Pharm Des 2003;9:2627-2642.
Estey EH.
How I treat older patients with AML.
Blood 2000;96:1670-1673.
Farag SS et al.
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
Blood 2006;108:63-73.
Freireich EJ.
Arabinosyl cytosine: a 20-year update.
J Clin Oncol 1987;5:523-524.
Hann IM et al.
Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.
Blood 1997;89:2311-2318.
Jehn U, Heinemann V.
New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA.
Anticancer Res 1991;11:705-711.
Lowenberg B et al.
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
N Engl J Med 2003;349:743-752.
Mayer RJ et al.
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
N Engl J Med 1994;331:896-903.
Miyawaki S et al.
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Cancer 2005;104:2726-2734.
Moore JO et al.
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.
Blood 2005;105:3420-3427.
O'Dwyer PJ et al.
Etoposide (VP-16-213). Current status of an active anticancer drug.
N Engl J Med 1985;312:692-700.
Plunkett W et al.
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
Semin Oncol 1993;20:2-12.
Pulsoni A et al.
Survival of elderly patients with acute myeloid leukemia.
Haematologica 2004;89:296-302.
Riva CM, Rustum YM, Preisler HD.
Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
Semin Oncol 1985;12:1-8.
Rustum YM, Riva C, Preisler HD.
Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C.
Semin Oncol 1987;14:141-148.
Sanz MA et al.
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.
Blood 2004;103:1237-1243.
Schlenk RF et al.
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
J Clin Oncol 2004;22:3741-3750.
Vogler WR et al.
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
J Clin Oncol 1992;10:1103-1111.
Weick JK et al.
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
Blood 1996;88:2841-2851.
Wheatley K.
A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
Br J Haematol 1998;103:100-109.
Wiernik PH et al.
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Blood 1992;79:313-319.
© ONKODIN 2002-2011 | Kopieren nur für persönliche Verwendung genehmigt. |